Chronic kidney disease in type 2 diabetes — indication assessment

§1Assessment

§1.1Definition

Persistent reduction in estimated glomerular filtration rate or persistent albuminuria in the context of type 2 diabetes, staged by eGFR and urine albumin-to-creatinine ratio.

§1.2Anchor and additional outcomes

The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.

1. Composite kidney outcome (kidney failure, sustained ≥50 % eGFR decline, kidney or cardiovascular death)
2. Annual eGFR slope
3. Change in urine albumin-to-creatinine ratio

§1.3State of the evidence

The Institute assesses 2 compounds in this indication, drawing on 15 trial records and 1 evidence synthesis. ^[1,2]

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185
2. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet 2021;397(10278):971–984. doi:10.1016/S0140-6736(21)00213-0 · PMID 33667417

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.